Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075100 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone + Carboplatin Metastatic Breast Cancer
A Phase 2 study, sponsored by US Oncology Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT01075100 is a Phase 2 study that has completed, run by US Oncology Research. The registered enrollment target is 103 participants.
The verdict
NCT01075100, a Phase 2 study, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A Phase I study of ixabepilone plus carboplatin in solid tumor patients demonstrated the safety of this combination at the doses and schedule proposed for this Phase II trial (BMS data on file).
Interventions
- DRUG Carboplatin
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01075100
The ClinicalTrials.gov registry entry for NCT01075100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01075100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01075100 about?
NCT01075100 is a clinical study titled "Ixabepilone + Carboplatin Metastatic Breast Cancer". Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination wi...
What is the current status of trial NCT01075100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2010-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01075100?
The interventions under investigation include: Carboplatin (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT01075100?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.